![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NEUROPHARMACOLOGY
Pharmacodynamics in the Brain, Cerebrospinal Fluid, and Plasma in Young (Plaque-Free) Tg2576 Mice Using the 
-Secretase Inhibitor N2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575)
Department of Neurobiology, Pharmacia Corporation, Kalamazoo, Michigan
A previous study by us suggests the utility of cerebrospinal fluid (CSF) and plasma A
as biomarkers of - or 
-secretase inhibition. The present study characterized further A pharmacodynamics in these tissues from Tg2576 mice and examined their correlation with brain A after acute treatment with a potent -secretase inhibitor, N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575). A single dose of LY-411575 dose-dependently (0.1–10 mg/kg p.o.) reduced A(1-40) and A(1-42) in the CSF and the brain. In contrast, plasma A levels were increased by 0.1 mg/kg LY-411575 and were followed by a dose-dependent reduction at higher doses. The time courses of A reduction and recovery were distinct for the three tissues: maximal declines in A levels were evident by 3 h in the CSF and plasma but not until 9 h in the brain. A recovery in A levels was underway in the CSF by 9 h and nearly completed by 24 h in all tissues. The differential time courses in the three compartments do not seem to be due to pharmacokinetic factors. Five days of twice-daily treatment with LY-411575 not only sustained the A reductions in all tissues but also significantly augmented the efficacy in the brain and plasma. The increased efficacy occurred in the absence of compound accumulation and was consistent with the recovery rates in each compartment. Overall, A in the CSF and not plasma seems to be a better biomarker of brain A reduction; however, the time course of A changes needs to be established in clinical studies.
Address correspondence to: Dr. Thomas A. Lanz, Pfizer, Inc., Eastern Point Road, MS# 8220-4183, Groton, CT 06340. E-mail: thomas.a.lanz{at}pfizer.com
This article has been cited by other articles:
|
|
 |
|
  D. Abramowski, K.-H. Wiederhold, U. Furrer, A.-L. Jaton, A. Neuenschwander, M.-J. Runser, S. Danner, J. Reichwald, D. Ammaturo, D. Staab, et al. Dynamics of A{beta} Turnover and Deposition in Different {beta}-Amyloid Precursor Protein Transgenic Mouse Models Following {gamma}-Secretase Inhibition J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 411 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Goldstein, Y. Cao, T. Fiedler, J. Toyn, L. Iben, D. M. Barten, M. Pierdomenico, J. Corsa, C. V. C. Prasad, R. E. Olson, et al. Ex Vivo Occupancy of {gamma}-Secretase Inhibitors Correlates with Brain beta-Amyloid Peptide Reduction in Tg2576 Mice J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 102 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Czirr, S. Leuchtenberger, C. Dorner-Ciossek, A. Schneider, M. Jucker, E. H. Koo, C. U. Pietrzik, K. Baumann, and S. Weggen Insensitivity to Abeta42-lowering Nonsteroidal Anti-inflammatory Drugs and {gamma}-Secretase Inhibitors Is Common among Aggressive Presenilin-1 Mutations J. Biol. Chem., August 24, 2007; 282(34): 24504 - 24513. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Hyde, N. A. McHugh, J. Chen, Q. Zhang, D. Manfra, A. A. Nomeir, H. Josien, T. Bara, J. W. Clader, L. Zhang, et al. Studies to Investigate the in Vivo Therapeutic Window of the {gamma}-Secretase Inhibitor N2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 Mouse J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1133 - 1143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Lanz, M. J. Karmilowicz, K. M. Wood, N. Pozdnyakov, P. Du, M. A. Piotrowski, T. M. Brown, C. E. Nolan, K. E. G. Richter, J. E. Finley, et al. Concentration-Dependent Modulation of Amyloid-beta in Vivo and in Vitro Using the {gamma}-Secretase Inhibitor, LY-450139 J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 924 - 933. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Masters and K. Beyreuther Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the A{beta} amyloid pathway Brain, November 1, 2006; 129(11): 2823 - 2839. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Nyborg, T. B. Ladd, K. Jansen, T. Kukar, and T. E. Golde Intramembrane proteolytic cleavage by human signal peptide peptidase like 3 and malaria signal peptide peptidase FASEB J, August 1, 2006; 20(10): 1671 - 1679. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Chen, E. A. Eckman, and C. B. Eckman Reductions in levels of the Alzheimer's amyloid {beta} peptide after oral administration of ginsenosides FASEB J, June 1, 2006; 20(8): 1269 - 1271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Best, M. T. Jay, F. Otu, I. Churcher, M. Reilly, P. Morentin-Gutierrez, C. Pattison, T. Harrison, M. S. Shearman, and J. R. Atack In Vivo Characterization of Abeta(40) Changes in Brain and Cerebrospinal Fluid Using the Novel {gamma}-Secretase Inhibitor N-[cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the Rat J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 786 - 790. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Reedijk, S. Odorcic, L. Chang, H. Zhang, N. Miller, D. R. McCready, G. Lockwood, and S. E. Egan High-level Coexpression of JAG1 and NOTCH1 Is Observed in Human Breast Cancer and Is Associated with Poor Overall Survival Cancer Res., September 15, 2005; 65(18): 8530 - 8537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Best, M. T. Jay, F. Otu, J. Ma, A. Nadin, S. Ellis, H. D. Lewis, C. Pattison, M. Reilly, T. Harrison, et al. Quantitative Measurement of Changes in Amyloid-{beta}(40) in the Rat Brain and Cerebrospinal Fluid following Treatment with the {gamma}-Secretase Inhibitor LY-411575 [N2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide] J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 902 - 908. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Barten, V. L. Guss, J. A. Corsa, A. Loo, S. B. Hansel, M. Zheng, B. Munoz, K. Srinivasan, B. Wang, B. J. Robertson, et al. Dynamics of {beta}-Amyloid Reductions in Brain, Cerebrospinal Fluid, and Plasma of {beta}-Amyloid Precursor Protein Transgenic Mice Treated with a {gamma}-Secretase Inhibitor J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 635 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Lanz, G. J. Fici, and K. M. Merchant Lack of Specific Amyloid-{beta}(1-42) Suppression by Nonsteroidal Anti-Inflammatory Drugs in Young, Plaque-Free Tg2576 Mice and in Guinea Pig Neuronal Cultures J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 399 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Nyborg, K. Jansen, T. B. Ladd, A. Fauq, and T. E. Golde A Signal Peptide Peptidase (SPP) Reporter Activity Assay Based on the Cleavage of Type II Membrane Protein Substrates Provides Further Evidence for an Inverted Orientation of the SPP Active Site Relative to Presenilin J. Biol. Chem., October 8, 2004; 279(41): 43148 - 43156. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
